Longitude Prize on ALS
The Longitude Prize on ALS funds global teams using AI and computational methods to discover and validate new therapeutic targets for ALS through staged awards and a final grand prize.
Funder: ALS Association
Due Dates: December 3, 2025 (Stage 1, closed) | April 30, 2028 (Stage 3) | August 31, 2030 (Winner applications close)
Funding Amounts: £7.5 million (~$10 million USD) total; staged awards: £100,000 (Discovery, 20 teams) → £200,000 (Prioritise, 10 teams) → £500,000 (Validate, 5 teams) → £1,000,000 (Grand Prize)
Summary: Major international competition supporting AI-driven discovery and validation of new therapeutic targets for ALS, with multi-stage funding and a final grand prize.
Key Information: Open to global multidisciplinary teams; next application deadline is April 2028 for Stage 3.
Description
The Longitude Prize on ALS is a global, multi-stage competition aimed at accelerating drug discovery for amyotrophic lateral sclerosis (ALS) using artificial intelligence and advanced computational methods. With a total prize fund of £7.5 million (~$10 million), the initiative seeks to uncover and validate novel therapeutic targets for ALS by supporting multidisciplinary teams through a structured sequence of funding rounds. The prize is designed to transform the landscape of ALS research by providing access to unique datasets, technical support, and staged financial awards, culminating in a £1 million grand prize for the team that delivers the most promising validated therapeutic target.
